Peptide Lab

Tirzepatide

$144.99

In stock

Tirzepatide is a synthetic peptide that activates GIP and GLP-1 receptors, two hormone pathways involved in appetite and blood-glucose regulation. FDA-approved formulations are administered by once-weekly subcutaneous injection. Its clinical research has demonstrated benefits for weight management and blood-glucose control in specific patient populations.

SKURC-ST-TIRZ-40MG
ManufacturerStrandix Peptides
FormLyophilized Powder
Strength40 mg
Size3 mL Vial
Reported Result>99%
StockIn stock
Documentation StatusPending Final COA

Product Description

Tirzepatide is a synthetic peptide that activates GIP and GLP-1 receptors, two hormone pathways involved in appetite and blood-glucose regulation. FDA-approved formulations are administered by once-weekly subcutaneous injection. Its clinical research has demonstrated benefits for weight management and blood-glucose control in specific patient populations.

Tirzepatide is the active ingredient in Mounjaro and Zepbound, prescription medications with distinct approved uses.

What research has shown:

Substantial weight reduction: In the 2,539-participant SURMOUNT-1 trial, adults with obesity or overweight and a weight-related complication, without diabetes, experienced average weight reductions of 15.0%–20.9% across treatment groups at 72 weeks, compared with 3.1% with placebo. Treatment included dietary and physical-activity support. These averages do not guarantee individual results.

Improved blood-glucose control: In SURPASS-2, adults with type 2 diabetes inadequately controlled with metformin experienced average HbA1c reductions of approximately 2.0–2.3 percentage points over 40 weeks.

Reduced appetite and food intake: These effects contribute to its weight-management activity. Zepbound is approved, alongside a reduced-calorie diet and increased physical activity, for long-term weight reduction and maintenance in eligible adults.

Improved obstructive sleep apnea in a defined population: Zepbound is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

Important safety considerations: Common adverse effects include nausea, diarrhea, vomiting, and constipation. More serious risks include pancreatitis, gallbladder problems, and dehydration-related kidney injury. Tirzepatide carries a boxed warning concerning thyroid C-cell tumors observed in rats; whether this risk applies to humans is unknown. Approved products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.

Storage and handling: Keep unopened lyophilized material sealed, protected from light and moisture, and stored at the temperature specified by the manufacturer. Confirm sequence, counterion, assay, purity, water content, and stability on the COA. Do not publish reconstitution or administration instructions.

For laboratory research use only. Not for human or animal consumption.
Lab analysis

Third-party testing status.

Batch / LotReported ResultTestedPartnerStatusDocument